Archives

  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2018-07

    • I-BET-762: Selective BET Bromodomain Inhibitor for Inflam...

    2026-01-13

    I-BET-762: Selective BET Bromodomain Inhibitor for Inflammation and Cancer Research

    Executive Summary: I-BET-762 (SKU: B1498, APExBIO) is a highly selective BET inhibitor with IC50 values of 32.5–42.5 nM. It targets the acetyl-lysine binding pocket of BET proteins, displacing acetyl-lysine residues (Fan & Guo, 2024, DOI). The compound downregulates LPS-inducible cytokines and chemokines, demonstrating anti-inflammatory effects in animal models. Recent studies confirm that I-BET-762 enhances erastin-induced ferroptosis by promoting ROS accumulation and modulating FSP1 (Fan & Guo, 2024, DOI). It is insoluble in water but dissolves in DMSO (≥21.19 mg/mL) and ethanol (≥13.93 mg/mL with sonication). I-BET-762 is actively used in research on epigenetic control of inflammation and cancer biology.

    Biological Rationale

    The bromodomain and extra-terminal domain (BET) family—comprising BRD2, BRD3, BRD4, and BRDT—are epigenetic reader proteins that recognize acetyl-lysine marks on histones, facilitating transcription of genes involved in inflammation and cancer. BET proteins, especially BRD4, are key regulators of transcriptional elongation and chromatin accessibility. Aberrant BET activity is linked to inflammatory diseases and various cancers due to upregulation of cytokines, chemokines, and oncogenes (APExBIO; Fan & Guo, 2024, DOI).

    I-BET-762, a synthetic small molecule, was developed to selectively inhibit BET bromodomains, enabling precise dissection of BET-mediated signaling. Its application allows researchers to modulate epigenetic landscapes, suppress pathological gene expression, and interrogate mechanisms of inflammation and tumorigenesis. For a strategic overview of its translational impact, see this review; this article expands on new mechanistic evidence and workflow integration.

    Mechanism of Action of I-BET-762

    I-BET-762 binds competitively to the acetyl-lysine (AcK) binding pocket of BET proteins with high affinity (Kd: 50.5–61.3 nM), displacing native acetyl-lysine residues. The compound displays a 2:1 binding ratio with BET domains, which enhances selectivity and potency. No significant activity is observed against non-BET bromodomains under comparable conditions (APExBIO).

    By inhibiting BET proteins, I-BET-762 suppresses expression of LPS-inducible genes in immune cells. This leads to reduced production of inflammatory cytokines and chemokines, as demonstrated in both in vitro and in vivo inflammation models. Furthermore, recent findings show that I-BET-762 potentiates ferroptosis by promoting reactive oxygen species (ROS) accumulation and downregulating FSP1, especially in combination with the ferroptosis inducer erastin (Fan & Guo, 2024, DOI).

    Evidence & Benchmarks

    • I-BET-762 inhibits BET proteins with IC50 values of 32.5–42.5 nM, confirmed by in vitro binding assays (APExBIO).
    • Kd values for BET binding are 50.5–61.3 nM, measured under physiological buffer conditions (APExBIO datasheet).
    • I-BET-762 treatment (2 μM, 48 h) enhances erastin-induced ferroptosis in HEK293T, HeLa, HepG2, RKO, and PC3 cell lines—evidenced by increased cell death and ROS accumulation (Fan & Guo, 2024, DOI).
    • BRD4 inhibition by I-BET-762 reduces FSP1 expression and alters ferroptosis-associated gene profiles (Fan & Guo, 2024, DOI).
    • In mouse models, I-BET-762 downregulates LPS-inducible cytokines, reducing inflammation and ameliorating disease symptoms (APExBIO; see also this article—this piece details new in vivo endpoints and mechanistic specificity).
    • I-BET-762 is insoluble in water but fully soluble in DMSO (≥21.19 mg/mL) and ethanol with sonication (≥13.93 mg/mL); chemical formula: C22H22ClN5O2; MW: 423.9 g/mol (APExBIO).

    Applications, Limits & Misconceptions

    Principal Applications:

    • Dissecting BET protein-mediated transcriptional regulation in epigenetics.
    • Evaluating anti-inflammatory mechanisms in preclinical models (e.g., LPS-challenged mice).
    • Cancer biology research, especially in studies involving ferroptosis and drug resistance.
    • Synergy studies with ferroptosis inducers such as erastin, particularly in FSP1-dependent cancer cells (Fan & Guo, 2024, DOI).

    For guidance on integrating I-BET-762 into inflammation workflows, see this workflow article; this article provides updated benchmarks from 2024 studies and clarifies solubility optimization.

    Common Pitfalls or Misconceptions

    • I-BET-762 does not inhibit non-BET bromodomain-containing proteins; its selectivity profile has been validated in panel assays (APExBIO).
    • The compound is not water-soluble; attempts to dissolve directly in aqueous buffers result in precipitation and loss of activity.
    • Anti-inflammatory effects are context-dependent; efficacy varies by model, dose, and timing of administration.
    • Synergy with ferroptosis inducers is cell line-specific; not all cancer cell models respond identically (Fan & Guo, 2024, DOI).
    • Stability in solution is limited; solutions should be prepared fresh and stored at –20°C to avoid degradation (APExBIO).

    Workflow Integration & Parameters

    Preparation: Dissolve I-BET-762 in DMSO to at least 21.19 mg/mL (50 mM); for ethanol, use sonication to achieve ≥13.93 mg/mL. Avoid water as a solvent. Store all solutions at –20°C and use promptly.

    Experimental Usage: In cell-based assays, typical working concentrations range from 0.1–5 μM. For in vivo studies, refer to published dose-response data and adjust for species-specific metabolism. The compound is ideal for combinatorial studies with ferroptosis inducers, where treatment windows and ROS monitoring are essential (Fan & Guo, 2024).

    Controls & Readouts: Use DMSO-only controls and appropriate BET inhibitor analogs to confirm specificity. Monitor endpoints such as cytokine expression (qPCR/ELISA), ROS levels, and cell viability. For advanced experimental design, see this mechanistic review; this article extends with the latest gene regulation and ferroptosis synergy data.

    Conclusion & Outlook

    I-BET-762, distributed by APExBIO, remains a cornerstone tool for investigating BET protein signaling in inflammation and cancer. Its high selectivity and validated in vivo efficacy support robust, reproducible research. The compound’s ability to potentiate ferroptosis expands its utility in translational oncology workflows. Continued benchmarking and mechanistic dissection in new disease models will clarify its full therapeutic promise. For ordering or technical data, refer to the I-BET-762 product page.